

EchoLaser presentation

European Conference on Interventional Oncology - ECIO 2018

Vienna | April 21-25, 2018

ECIO Congress took place at the Reed Messe Wien and Elesta took part to the event with the booth and the Hands-On Device Training on EchoLaser, which was attended with the support of Dr. Mauri from IEO, Milan. The Hands-on session aroused great interest among the participants since they had the chance to attend a brief presentation of the EchoLaser System and to perform ablation procedures simulations on a cow liver phantom under the indications of Dr. Mauri who explained them the main features and functionalities of the system. During the Congress Dr. Patelli from Pesenti Fenaroli Hospital, Alzano Lombardo, presented the updated results on SoracteLite treatment, as reported below:



Accepted Abstract (Reference Number 1902.7 in ECIO 2018 Abstract Book)
Transperineal ultrasound-guided laser ablation for the treatment of benign prostatic hyperplasia: preliminary results

Purpose

To assess safety and efficacy of ultrasound-guided (US-g) transperineal laser ablation (TPLA) in treating benign prostatic hyperplasia (BPH).

Material and Methods

Material and Methods: Fifty-five patients (age 72.6 ± 10.4 years, range 58-93) suffering from obstructive syndrome secondary to BPH underwent TPLA using continuous wave (CW) diode laser source operating at 1064nm (EchoLaser SoracteLite, Elesta s.r.l., Calenzano (FI), Italy). Under US-g depending on basal volume up to two 21G introducer-needles for each lobe were inserted via transperineal approach. Each treatment was performed with a fixed power protocol (3W) changing the illumination time case by case according to prostate volume. The efficacy of the treatment was evaluated considering the changes of international prostate symptoms score (IPSS), quality of life (QoL), post-void residual (PVR), peak urinary flow rate (Qmax) and prostate volume. Mean hospital stay and mean catheterization time were measured.

Results

In all patients the treatment was successful without intraoperative and perioperative complications. Mean operation time was 43.3 ± 8.7 min, mean ablation time 15.9 ± 3.9 min, mean energy deployed $11,470.0 \pm 3,570.6$ J, mean hospital stay 1.5 ± 0.4 days and mean catheterization time after the procedure 14.4 ± 7.7 days. Mean follow-up was 11.5 months (range 4-36). IPSS improved from 22.2 to 7.7 ($P < 0.001$), QoL from 4.5 to 1 ($P < 0.001$), Qmax from 7.6 to 13.3 ml/s ($P = 0.001$), PVR from 148.0 to 58.2 ml ($P < 0.001$), mean prostate volume from 80.6 to 52.6 ml ($P < 0.001$). No major complications occurred.

Conclusion

TPLA is a novel option to treat patients affected by BPH. The study demonstrated that this approach is efficacious and safe with significant and durable results.

Thanks to the extraordinary support from our Italian KOLs and distributors we were able to get in touch with important KOLs in different radiology fields.



UPCOMING EVENTS:

February 7-8, 2019

In Milan, Italy, at Palazzo delle Stelline

Trattamenti Percutanei nella Patologia Tiroidea 2019

February 28 - March 4, 2019

In Vienna, Austria, at Austria Center Vienna

European Congress of Radiology – ECR 2019

SoracteLite Round Table - WCE Congress

SoracteLite treatment – state of the art and perspectives

Geneve | September 18-19, 2018

The event took place in Clinique La Colline, one of Elesa international centres performing SoracteLite Treatment. On September 18th, during the Round Table, SoracteLite Treatment was presented by Dr. Regusci (Geneve, SIPC), Prof. De Reijke (Amsterdam, AMC University Hospital) and Dr. Patelli (Alzano Lombardo – Pesenti Fenaroli Hospital, the pioneer of SoracteLite). The aim was to let the participants have up to date information on this innovative EchoLaser application, with particular attention to treatment indications, clinical publications and possible future applications, both for the treatment of benign and malignant urological pathologies.



Here below is reported the program and Scientific Board of the Round Table:

Scientific Board

T.M. De Reijke, M.M. Dresse, L. Jianxing, G. Patelli, S. Regusci

- 17:30 – 17:45** **Regusci - Dresse:** Welcome speech
- 17:45 – 18:15** **Patelli:** SoracteLite for the treatment of BPH
- 18:15 – 18:45** **Regusci:** SoracteLite for the Focal Treatment of Prostatic Cancer
- 18:45 – 19:15** **De Reijke:** Need for an International Clinical Registry: the AMC project
- 19:15 – 19:45** Special talk on X-ray free PCNL in challenge cases by guest speaker Prof. **Jianxing Li:** best practice sharing China-Europe
- 19:45 – 20:30** Q&A



The second day of the Course, all the doctors were welcomed in Clinique La Colline to attend LIVE SoracteLite procedures. Dr. Regusci and his team performed 2 BPH and one prostatic cancer treatments in the OR, while the participants attended the procedures through video/ audio connections. Thanks to the audio connection the doctors were able to talk directly with Dr. Regusci and his team to ask questions about the procedure. All the doctors were positively impressed from the innovations of the procedure (trans-perineal approach which allow to avoid every contact with the surrounding structures – urethra and bladder, absence of tissue removal, absence of anesthesia, absence of complications related to the procedure so far, with a follow-up of up to 4 years) and its clinical results.

International School of Thyroid Ultrasonography and Ultrasound assisted procedure – Second Edition 2018

Albano Laziale | September 20-21, 2018

The training course took place in Regina Apostolorum Hospital, Albano Laziale, Rome. Ten doctors from from Italy and abroad participated spontaneously in this edition of the course in order to have up-to-date knowledge on thyroid ultrasonography and on laser treatment for benign and malignant structures in the neck. The course had both theoretical and practical sessions: presentations for Dr. Bizzarri and Prof. Papini form the theoretical part; Live cases and hands on section form the practise part. The combination of theory and practise is very useful for doctors to contextualize ModiLite treatment. Participant doctors were very impressive in the micro-invasive approach and simplicity of Echolaser Therapy and most of these were contacts from the distributors because interest in introducing the procedure and technology in their Hospital.




World Congress of Endourology 2018

Paris | September 21-23, 2018

Elesta supported for the first time the event presenting the EchoLaser system in the SoracteLite configuration.

During the congress Dr. Patelli exposed the up to date clinical data of SoracteLite treatment in a moderated poster session.



MP6-18 Ultrasound-Guided Transperineal Laser Ablation: a novel modality for the treatment of benign prostatic hyperplasia

Paris | September 21-23, 2018

Introduction: Over the last decade, there has been effort to identify new technologies aimed at a minimally invasive and rapid therapy for patient affected by symptomatic Benign Prostatic Hyperplasia.

Objective: to evaluate the safety and efficacy of the ultrasound guided Transperineal Laser Ablation (TPLA) in the treatment of Benign Prostatic Hyperplasia (BPH).

Methods: 67 patients (age 73.1 ± 10.7 years, range 51-93) suffering from obstructive syndrome secondary to BPH, (28/67 patients urinary catheter carrier), were treated with TPLA using continuous wave (CW) diode laser source operating at 1064 nm wavelength. By ultrasound guided transperineal approach, depending on the glandular volume, up to two fibres through 21 G needles for each lobe, were inserted in the prostate. Each treatment were performed with a standard protocol (3W power with maximum 1,800J delivery for each fibre illumination and eventually pull back) according to the prostate volume. The efficacy of the treatment was evaluated considering the changes of International prostate Symptoms Score (IPSS), the Quality of Life score (QoL), Post-Void Residual (PVR) urine, peak urinary flow rate (Qmax) and prostatic volume. The mean hospital stay and mean catheterization time were measured.

Results: All 67 patients were treated without procedural complications. The mean operation time was 40.3 ± 7.4 minutes, mean ablation time 15.9 ± 3.9 minutes, mean energy deployed $10,746.3 \pm 4,033.3$ J, mean hospital time 1.5 ± 0.4 days, mean catheterization time after the procedure was 24.2 ± 14.6 days. Mean follow up was 14 months (range 3-39 months). IPSS improved from 22.3 to 7.7 ($P < 0.001$), QoL from 4.4 to 0.8 ($p < 0.001$), Qmax from 9.2 to 12.1 ml/sec ($p = 0.001$), PVR from 151.7 to 30.2 ml ($p < 0.001$), prostatic volume from 74.7 to 49.5 ml ($p < 0.001$). No major complications occurred.

Conclusions: TPLA is a novel option to treat patients affected by BPH. This approach was efficacious and safe with significant and durable results.



First ModiLite procedure with EchoLaser performed in "Clinic City - St. George" Hospital of Montana

Bulgaria | September 26, 2018

On September 26, 2018, at the "Clinic City - St. George" Hospital of Montana, one of the most important reference centres in Bulgaria, and in the whole South-Eastern Europe, the first ModiLite procedure with EchoLaser in Bulgaria has been performed.

The Assoc. Prof. Tsvetin Genadiev and Dr. Georgi Chakarov of the City Clinic Hospital "St. George" in Montana were supported in the performance of the treatments by the Italian KOL on ModiLite procedure Prof. Renato Esposito (Clinica Madonna - IGreco Ospedali Riuniti srl - Cosenza, Italy), who performed over 600 successful treatments so far. Prof. Genadiev and Dr. Chakarov are also the first native physicians certified for the full implementation of this innovative technology and they have undergone specialized training for bloodless and micro-invasive therapy with EchoLaser in Pesenti Fenaroli Hospital, one of the Italian reference centres in Bergamo.

The Montana Clinic is also a pioneer in the treatment of benign prostatic hyperplasia with EchoLaser - in early June this year, Professor Gianluigi Patelli, with extensive experience in bloodless and micro-invasive therapy in Italy, Poland, Switzerland and China, together with Dr. Chakarov, a Urologist from the City Clinic Hospital - St. George Montana, performed three successful SoractelLite procedures. These were the first such interventions in Bulgaria and Southeast Europe.

"Treatment with EchoLaser is now fully available to Bulgarian patients as well. University Hospital - St. George Montana is ready to receive patients from Montana, the region, the country and neighbouring countries. The partnership with specialists from Italy and all over Europe will continue and they will periodically visit the Montana Center. But it is of the utmost importance not only to accept foreign specialists but also to train our extremely good doctors to keep up with the latest innovations from the world of fast-growing medicine and to provide Bulgarian patients with world-class treatments" said Dragan Blagoev, OA, City Clinic of St. George Montana.




"Love the life!" – Clinic Fundeni Institute

Bucarest | 3-6 October, 2018

Under the sponsorship of Fundeni Hospital and with kind support of Dr. Di Costanzo, two PBLite treatment were performed. Dr. Mugur Cristian Grasu and his team were trained on how to plan the treatment, position the needles and how to perform the follow-up procedure. All the procedure was recorded and shown at the annual Clinical Conference entitled „IUBEȘTE VIAȚA!“ which took place in Clinic Fundeni Institute, Bucarest.

During the event a satellite symposia with two lectures about PBLite treatment was held by Dr. Mugur Cristian Grasu (Clinic Fundeni Institute, Bucarest), Dr. Giovanni Mauri (IEO, Milan), who presented PBLite treatment and a panoramic view of all Echolaser application, shared their clinical experience and showed LIVE videos of the procedure.

Both events (live cases and Congress) were linked together and there was a significant interest raised from the professional community.



Laser ablation Training workshop

Geneve | October 15, 2018

The event took place in Clinique La Colline, one of Elesta international centres performing SoractelLite Treatment. 21 Chinese doctors, sent by Esaote China, participated to this training according to their interest in laser ablation treatment and technology in particular for prostate application (SoractelLite).

During the workshop, the urologist Dr. Regusci (Geneve, SIPC) and his team performed two SoractelLite live cases (one on Prostate affected by BPH and one on prostate cancer) in the OR, while the participants attended the procedures through video/audio connections in a dedicated multimedia room. After SoractelLite cases, Dr. Regusci and Chinese KOL (Prof. Tian Jiawei, 2nd Affiliated Hospital of Harbin Medical University and Prof. Zhang Lu, Shanghai Ruijin Hospital of Shanghai Jiaotong University) introduced in oral presentation Soractelite and ModiLite procedure in malignant and benign tumours/pathology.



Scientific Conference "100 years of Academic Surgery at the Medical University of Warsaw"

Warsaw | 15-17 November, 2018

The Scientific Conference "100 years of Academic Surgery at the Medical University of Warsaw" organised by the Department and Clinic of General, Transplant and Liver Surgery of the Medical University of Warsaw hosted many well-known and accomplished experts and specialists from leading hepatology, nephrology and transplantology centres, as well as vascular centres, from both Poland and abroad. During the event Dr. Di Costanzo (Cardarelli Hospital, Naples) held an oral presentation titled "**Micro-invasive Laser Thermal Ablation Therapy for the Treatment of HCC**" on 16 November.



17th AME National Congress

Rome | 8-11 November, 2018

The AME (Associazione Medici Endocrinologici) is the endocrinological scientific society founded with the aim of bringing together doctors who work daily in the Clinical Endocrinology sector in Italy, aiming to improve the assistance and defense of Endocrinology.

As part of the training and updating, the AME promoted and organized its 17th National Congress to be held at the Ergife Palace Hotel in Rome from 8 to 11 November 2018. The four days, full of events, hosted symposia, mini - courses, guidelines and discussions with experts through various sessions dedicated to updating in the main fields of endocrinology, with a growing focus on the diseases of wider interest: diseases of the thyroid, diabetes, osteoporosis and metabolism.

On Saturday 10th recent updates in the management of thyroid nodules with mini-invasive procedures were discussed and presented by some of the most experienced Italian endocrinologists in a symposium entitled "Thyroid Nodules: mini-invasive procedures and their indications"

SIMPOSIO 8

Noduli tiroidei: le terapie mini-invasive e le loro indicazioni

Moderatori: E. Papini, B. Raggiunti

Le tecnologie disponibili

C.M. Pacella

Le indicazioni al trattamento nei noduli benigni

S. Monti

Le indicazioni al trattamento nella patologia maligna

G. Mauri

Limiti e complicanze

P.P. Limone


Take home messages

E. Papini

New Informative websites for patients

We are pleased to announce the update of our patient websites www.modilite.info and www.soractelite.info.

Completely renewed in their graphics and contents, the websites reports information on the pathologies and treatments with EchoLaser.



New publications on Echolaser Therapy

Benign Thyroid Nodule - ModiLite

Benign thyroid nodule unresponsive to radiofrequency ablation treated with laser ablation: a case report.

Oddo S, Balestra M, Vera L, Giusti M.

J Med Case Rep. 2018 May 11;12(1):127.

Percutaneous Ethanol Injection in Combination with Laser Ablation for a 100 ml Partially Cystic Thyroid Nodule.

Negro R, Greco G.

Case Rep Endocrinol. 2018 Feb 15;2018:8046378.

Malignant Thyroid Tumour - ModiLite

Ultrasound-guided laser ablation for local control of neck recurrences of medullary thyroid cancer. A feasibility study.

Persichetti A, Bizzarri G, Guglielmi R, Barnabei A, Bianchini A, Cocco C, Appetecchia M, Papini E.

Int J Hyperthermia. 2018 Sep 11:1-5.

Renal tumours - SoracteLite

Ultrasound-guided percutaneous laser ablation is safe and effective in the treatment of small renal tumors in patients at increased bleeding risk.

Sartori S, Mauri G, Tombesi P, Di Vece F, Bianchi L, Pacella CM

Int J Hyperthermia. 018;35(1):19-25.

Liver - PBLite

Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study.

Morisco F, Camera S, Guarino M, Tortora R, Cossiga V, Vitiello A, Cordone G, Caporaso N, Di Costanzo GG and Italian Liver Cancer (ITA.LI.CA) group

Oncotarget. 2018; 9:17483-17490.

Breast - AgathaLite

The Evolving Role of Ultrasound Guided Percutaneous Laser Ablation in Elderly Unresectable Breast Cancer Patients: A Feasibility Pilot Study.

Nori J, Gill MK, Meattini I, Delli Paoli C, Abdulcadir D, Vanzi E, Boeri C, Gabbriellini S, Giannotti E, Lucci F, Vezzosi V, De Benedetto D, Bicchierai G, Bianchi S, Sanchez L, Orzalesi L, Carmelo G, Miele V, Livi L, Casella D.

Biomed Res Int. 2018 Jun 11;2018:9141746.

Year 2018
Edition n.2
November

Echolaser news are available at
<http://www.elesta-echolaser.com/echolaser-magazine/>

Echolaser Club/contacts
Tel +39 055 8826807
Fax +39 055 7766698
e-mail info@elesta-echolaser.com

ModiLite
<http://modilite.info>

SoracteLite
<http://soractelite.info>

Elesta s.r.l.
Via Baldanzese 17 50041 Calenzano, Italy
Tel. +39 055 8826807 Fax +39 055 7766698
www.elesta-echolaser.com

Echolaser News and any files transmitted with it are confidential. The EchoLaser members are authorized to view and make a single copy of parts of its content for offline, personal, non-commercial use. The content may not be sold, reproduced, or distributed without our written permission. Any third-party trademarks, service marks and logos are the property of their respective owners. Any further rights not specifically granted herein are reserved.

ELESTA
Beyond Laser